Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aprameya EngineeringNSE:APRAMEYA -2.33%43 Debt-to-Equity is 0.10 as of Mar. 2026, which is 89% below its 10-year median of 0.94. GuruFocus rates NSE:APRAMEYA with a GF Score™ of 43/100. The stock has 6 warning signs investors should review. Among 703 Medical Devices & Instruments companies, Aprameya Engineering ranks better than 67.57% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Aprameya Engineering's Debt-to-Equity or its related term are showing as below:
NSE:APRAMEYA'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.1 Med: 0.94 Max: 1.8
Current: 0.1
During the past 7 years, the highest Debt-to-Equity Ratio of Aprameya Engineering was 1.80. The lowest was 0.10. And the median was 0.94.
NSE:APRAMEYA's Debt-to-Equity is ranked better than 67.57% of 703
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs NSE:APRAMEYA: 0.10
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Aprameya Engineering Debt-to-Equity Related Terms
Aprameya Engineering Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Aprameya Engineering's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:APRAMEYA vs ISRG, BDX, MDLN: Debt-to-Equity Comparison
For the Medical Instruments & Supplies subindustry, Aprameya Engineering's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aprameya Engineering Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Aprameya Engineering's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Aprameya Engineering's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aprameya Engineering (NSE:APRAMEYA) has a Debt-to-Equity of 0.10 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Aprameya Engineering and its competitors. This is 89% below median its historical median of 0.94. Over the past decade, Aprameya Engineering's Debt-to-Equity has ranged from 0.10 to 1.80. According to the industry distribution chart, Aprameya Engineering ranks #228 out of 703 companies in the Medical Devices & Instruments industry, placing it in the top 32.4%.
Is Aprameya Engineering's Debt-to-Equity too high?
Aprameya Engineering's current Debt-to-Equity of 0.10 is 89% below median its 10-year median of 0.94. Over the past 10 years, this metric has ranged from a low of 0.10 to a high of 1.80. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Aprameya Engineering's value of 0.10 is 56.5% below this industry median. Based on the distribution chart, Aprameya Engineering ranks #228 out of 703 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Aprameya Engineering has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Aprameya Engineering's Debt-to-Equity compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Aprameya Engineering ranks #228 out of 703 companies for Debt-to-Equity. This puts Aprameya Engineering in the upper half of its industry. The industry median Debt-to-Equity is 0.23. Aprameya Engineering's value of 0.10 is 56.5% below this benchmark. Historically, Aprameya Engineering's own Debt-to-Equity has ranged from 0.10 to 1.80 over the past decade. While the company's 10-year median is 0.94 vs. the industry median of 0.23, Aprameya Engineering has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 703 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aprameya Engineering's current Debt-to-Equity of 0.10 is 56.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Aprameya Engineering and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aprameya Engineering's current Debt-to-Equity is 0.10, which is 89% below median its own 10-year median of 0.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprameya Engineering stock overvalued right now?
Aprameya Engineering (NSE:APRAMEYA) has a current Debt-to-Equity of 0.10. The current Debt-to-Equity is 0.10, which is 89% below median its 10-year median of 0.94 and 56.5% below the Medical Devices & Instruments industry median of 0.23. Aprameya Engineering's overall GF Score™ is 43/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Aprameya Engineering (NSE:APRAMEYA), the current Debt-to-Equity is 0.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aprameya Engineering Ltd is engaged in the business of installation, set up & maintenance of Intensive Care Units (ICU), Neonatal Intensive Care Units (NICU), Pediatric Intensive Care Units (PICU), Operation Theatre, dialysis centres and prefabricated structure ward (hereinafter referred to as Healthcare Infrastructure projects) in the hospitals and medical care centers on turnkey basis with the supply of high-value healthcare equipment and diagnostic equipment to private hospitals, Government hospitals, and medical practitioners. The company has two Business segments: Trading of Medical support Equipment (Trading Sales) and Supplies for Infra Projects for health care sectors (Turnkey project supplies). Key revenue is generated from Trunkey Project Supply.
43GF Score
Get the complete analysis for NSE:APRAMEYA
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:APRAMEYA has been successfully added to your 
